Average Insider

Where insiders trade, we follow

$RVMD
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Healthcare
Sector
Biotechnology
Industry
Mark A. Goldsmith
CEO
616
Employees
$162.69
Current Price
$19.86B
Market Cap
52W Low$67.86
Current$162.6960.6% above low, 39.4% below high
52W High$224.31

Insider Activity Statistics

Aggregated buying and selling activity by time period
PeriodTypeInsidersTransactionsValueSharesBuy/Sell Ratio
1 weekBuys00---
Sells00--
2 weeksBuys00--All Sells
Sells212$6,886,887.8536,561
1 monthBuys00--All Sells
Sells213$7,318,834.7538,871
2 monthsBuys00--All Sells
Sells526$11,454,030.0859,796
3 monthsBuys00--All Sells
Sells992$85,328,124.36419,581
See activity going back 12 months โ€” create a free account

Insider Transactions

Recent purchases and sales by company insiders
DateInsiderTypeSharesPriceValueActions
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale5,776$182.09$1,051,752.42View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale800$185.04$148,029.04View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale600$187.34$112,402.26View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale1,900$184.02$349,646.74View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale2,700$182.87$493,750.08View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale500$190.99$95,497.00View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale400$186.41$74,565.52View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale200$189.17$37,834.00View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale9,486$191.94$1,820,743.79View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale9,889$192.84$1,907,000.69View Details
Nov 11, 2026
Anders Jack
Chief Financial Officer
Sale3,499$181.04$633,466.31View Details
Nov 9, 2026
Mancini Anthony
Chief Global Commercialization Officer
Sale811$200.00$162,200.00View Details
Oct 26, 2026
Mancini Anthony
Chief Global Commercialization Officer
Sale2,310$186.99$431,946.90View Details
Sep 29, 2026
Sandler Alan B.
Chief Development Officer
Sale1,000$202.81$202,812.70View Details
Sep 29, 2026
Sandler Alan B.
Chief Development Officer
Sale2,200$200.82$441,801.36View Details
Sep 29, 2026
Sandler Alan B.
Chief Development Officer
Sale301$204.72$61,621.44View Details
Sep 29, 2026
Sandler Alan B.
Chief Development Officer
Sale1,199$203.91$244,484.97View Details
Sep 29, 2026
Sandler Alan B.
Chief Development Officer
Sale1,609$201.72$324,573.76View Details
Sep 25, 2026
Cislini Jeff
SVP&General Counsel
Sale765$207.32$158,599.88View Details
Sep 25, 2026
Mancini Anthony
Chief Global Commercialization Officer
Sale3,121$200.54$625,885.34View Details

Upcoming Earnings

Scheduled earnings reports
No upcoming earnings scheduled

Past Earnings

Historical earnings results
Nov 4, 2026
EPS
Estimated-$2.34
ActualN/A
Revenue
Estimated$23.74M
ActualN/A
2 more earnings records available โ€” create a free account to see 12 months of history
Version: v26.11.1